Key Points
- Director Cyrus Harmon sold 10,000 shares on Jan. 20 at an average price of $26.88 for $268,800, reducing his stake by 1.36% to 727,770 shares; he also sold smaller blocks on Jan. 14 and Dec. 22.
- Olema shares opened at $26.29 and trade in a 52‑week range of $2.86–$36.26 with a $1.81 billion market cap and clear momentum (50‑day MA $26.18 vs 200‑day MA $13.80), but the company is unprofitable (negative EPS, P/E -14.06) with analysts forecasting about -2.33 EPS for the year.
- Analyst and institutional backdrop: eight Buy, one Hold and one Sell give a consensus "Moderate Buy" with an average price target of $41, and institutional investors own roughly 91.78% of the stock.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $26.88, for a total transaction of $268,800.00. Following the transaction, the director owned 727,770 shares of the company's stock, valued at approximately $19,562,457.60. This represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Cyrus Harmon also recently made the following trade(s):
- On Wednesday, January 14th, Cyrus Harmon sold 3,489 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $29.12, for a total value of $101,599.68.
- On Monday, December 22nd, Cyrus Harmon sold 2,881 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.53, for a total value of $82,194.93.
Olema Pharmaceuticals Price Performance
Olema Pharmaceuticals stock opened at $26.29 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $36.26. The stock has a market capitalization of $1.81 billion, a P/E ratio of -14.06 and a beta of 1.92. The stock has a fifty day moving average of $26.18 and a 200-day moving average of $13.80.
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its earnings results on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.05). On average, sell-side analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Persistent Asset Partners Ltd boosted its holdings in Olema Pharmaceuticals by 153.8% in the second quarter. Persistent Asset Partners Ltd now owns 58,333 shares of the company's stock valued at $248,000 after acquiring an additional 35,345 shares during the last quarter. Titleist Asset Management LLC bought a new position in Olema Pharmaceuticals during the 2nd quarter worth approximately $64,000. Diadema Partners LP lifted its position in shares of Olema Pharmaceuticals by 153.7% in the 2nd quarter. Diadema Partners LP now owns 253,657 shares of the company's stock worth $1,081,000 after purchasing an additional 153,657 shares during the period. Birchview Capital LP bought a new stake in shares of Olema Pharmaceuticals in the 2nd quarter valued at $571,000. Finally, Farther Finance Advisors LLC boosted its stake in shares of Olema Pharmaceuticals by 602.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company's stock valued at $29,000 after purchasing an additional 5,866 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
OLMA has been the subject of a number of research analyst reports. HC Wainwright increased their price objective on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday, December 11th. UBS Group assumed coverage on Olema Pharmaceuticals in a research note on Wednesday, January 7th. They issued a "buy" rating and a $45.00 price target for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Olema Pharmaceuticals in a research report on Wednesday, October 8th. Piper Sandler initiated coverage on Olema Pharmaceuticals in a research report on Wednesday, January 7th. They issued an "overweight" rating and a $40.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an "overweight" rating in a research note on Tuesday, November 18th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $41.00.
Get Our Latest Analysis on Olema Pharmaceuticals
About Olema Pharmaceuticals
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
